Genital Warts Clinical Trial
Official title:
A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine in Chinese Males 9 Through 14 Years Old and 3-Dose Regimen of V503 in Chinese Males 9 Through 19 Years Old
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in Chinese males 9 through 14 years of age, compared to the 3 dose regimen in Chinese males 20 through 26 years of age (from Merck Protocol V503-052). The primary hypothesis is that each of the 3-dose regimen in Chinese males aged 9 through 19 years and 2-dose regimens in Chinese males aged 9 through 14 years induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) at one month post last dose compared to the 3-dose regimen in Chinese adult males aged 20 through 26 years. A noninferiority margin of 0.67 in the GMT ratio (9 through 19 years of age or 9 through 14 years of age vs 20 through 26 years of age) is used for each HPV type.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
| Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
| Completed |
NCT01651949 -
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
|
Phase 3 | |
| Completed |
NCT00520598 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
|
Phase 2 | |
| Completed |
NCT00551187 -
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
|
Phase 2 | |
| Terminated |
NCT01468636 -
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
|
Phase 4 | |
| Recruiting |
NCT03296397 -
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
|
Phase 3 | |
| Completed |
NCT00674739 -
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
|
Phase 3 | |
| Recruiting |
NCT03948321 -
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts
|
N/A | |
| Completed |
NCT00862810 -
Alternate Dosing Schedules Study for HPV Vaccine
|
Phase 4 | |
| Completed |
NCT02280642 -
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
|
Phase 4 | |
| Completed |
NCT00092482 -
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT02188004 -
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
|
||
| Completed |
NCT01553994 -
Effectiveness Study of Gardasil on Condyloma
|
N/A | |
| Completed |
NCT00189293 -
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
|
Phase 4 | |
| Active, not recruiting |
NCT00092534 -
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
|
Phase 3 | |
| Completed |
NCT02462187 -
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
|
Phase 2 | |
| Completed |
NCT00501137 -
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT02750202 -
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
|
Phase 3 | |
| Active, not recruiting |
NCT02653118 -
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
|